ArticlemAbs2026
Mimic antibodies: leveraging ligand mimicry for epitope-targeted antibody discovery.
Article in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibodies are renowned for their ability to bind diverse targets with high affinity and specificity, yet identifying binders with predefined epitope specificity remains a major challenge. In this study, we investigate the concept of mimic antibodies-antibodies that recapitulate the binding mode of a target's cognate ligand. Through a systematic analysis of the Protein Data Bank (PDB), we show that such mimicry is widespread and arises through diverse structural mechanisms, such as single-loop, multi-loop and scattered interaction mimicry. These findings indicate that protein interfaces impose strong constraints on binding, leading to convergent interaction solutions that can be independently discovered by antibodies. Building on these findings, we developed a ligand-guided strategy to mine immune repertoire data by selecting antibodies whose predicted binding interfaces mimic the interaction motif of a cognate ligand. Applied to the interaction between interleukin-18 (IL-18) and its receptor alpha (IL-18RA), mimicry-guided screening of a 20,000-sequence repertoire yielded 31 candidates, 11 of which (35% hit rate) bound the IL-18RA D3 domain, with eight reaching sub-nanomolar affinities that surpass the cognate ligand. Our findings establish mimic antibodies as a promising strategy for rational antibody selection, engineering, and design, with broad implications for therapeutic antibody development and drug discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.